fullerene c60 has been researched along with Cardiovascular Diseases in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dhungana, S; Fennell, TR; Han, L; Holland, NA; Lewin, AH; Mortensen, NP; Pathmasiri, W; Shannahan, JH; Snyder, RW; Sumner, SC; Wingard, C | 1 |
| Brown, JM; Fennell, TR; Holland, NA; Lewin, AH; Sumner, SJ; Thompson, LC; Vidanapathirana, AK; Wingard, CJ | 1 |
| Todorovic-Markovic, B; Trajkovic, V; Trpkovic, A | 1 |
1 review(s) available for fullerene c60 and Cardiovascular Diseases
| Article | Year |
|---|---|
Toxicity of pristine versus functionalized fullerenes: mechanisms of cell damage and the role of oxidative stress.
Topics: Animals; Cardiovascular Diseases; Cell Survival; Eye Diseases; Fullerenes; Furans; Humans; Kidney Diseases; Mutagens; Nervous System Diseases; Oxidative Stress; Reactive Oxygen Species; Skin Diseases | 2012 |
2 other study(ies) available for fullerene c60 and Cardiovascular Diseases
| Article | Year |
|---|---|
Distribution and biomarkers of carbon-14-labeled fullerene C60 ([(14) C(U)]C60 ) in female rats and mice for up to 30 days after intravenous exposure.
Topics: Administration, Intravenous; Animals; Biomarkers; Biotransformation; Carbon Radioisotopes; Cardiovascular Diseases; Female; Fullerenes; Liver; Lung; Metabolic Clearance Rate; Metabolomics; Mice, Inbred C57BL; Organ Specificity; Oxidative Stress; Rats, Sprague-Dawley; Species Specificity; Spleen; Tissue Distribution | 2015 |
The need for reflective consideration of an integrative understanding of cardiovascular consequences to PVP formulated C60 exposure.
Topics: Animals; Carboxylic Acids; Cardiovascular Diseases; Chemistry, Pharmaceutical; Fullerenes; Humans; Nanostructures; Particle Size; Risk Assessment; Risk Factors; Solubility | 2014 |